These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37204724)

  • 21. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
    Bates SM; Weitz JI
    Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery.
    Zucker ML; Koster A; Prats J; Laduca FM
    J Extra Corpor Technol; 2005 Dec; 37(4):364-8. PubMed ID: 16524153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin use during radiofrequency catheter ablation procedures in two patients with a history of heparin-induced thrombocytopenia.
    Baetz BE; Gerstenfeld EP; Kolansky DM; Spinler SA
    Pharmacotherapy; 2010 Sep; 30(9):952. PubMed ID: 20812431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ecarin-Based Methods for Measuring Thrombin Inhibitors.
    Gosselin RC
    Methods Mol Biol; 2023; 2663():355-367. PubMed ID: 37204723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
    Seybert AL
    Pharmacotherapy; 2002 Jun; 22(6 Pt 2):112S-118S. PubMed ID: 12064568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of bivalirudin.
    Reed MD; Bell D
    Pharmacotherapy; 2002 Jun; 22(6 Pt 2):105S-111S. PubMed ID: 12064567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.
    Veale JJ; McCarthy HM; Palmer G; Dyke CM
    J Extra Corpor Technol; 2005 Sep; 37(3):296-302. PubMed ID: 16350384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin: a new generation antithrombotic drug.
    Scatena R
    Expert Opin Investig Drugs; 2000 May; 9(5):1119-27. PubMed ID: 11060732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
    Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
    Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of bivalirudin in patients with renal impairment.
    Robson R
    J Invasive Cardiol; 2000 Dec; 12 Suppl F():33F-6. PubMed ID: 11156732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin: a new promising direct antithrombin.
    Bhambhani A; Meier B
    Indian Heart J; 2007; 59(3):288-94. PubMed ID: 19124943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
    Ramana RK; Lewis BE
    Vasc Health Risk Manag; 2008; 4(3):493-505. PubMed ID: 18827868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
    Koster A; Loebe M; Hansen R; Bauer M; Mertzlufft F; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1278-83. PubMed ID: 10838548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing management of hirudin anticoagulation.
    Measday MA; Zucker ML; Pan CM; LaDuca FM
    J Extra Corpor Technol; 2005 Mar; 37(1):66-70. PubMed ID: 15804161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia.
    Jabr K; Johnson JH; McDonald MH; Walsh DL; Martin WD; Johnson AC; Pickett JM; Shantha-Martin U
    J Extra Corpor Technol; 2004 Jun; 36(2):174-7. PubMed ID: 15334761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G; Roser M; Nauck M
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration.
    Casserly IP; Kereiakes DJ; Gray WA; Gibson PH; Lauer MA; Reginelli JP; Moliterno DJ
    Thromb Res; 2004; 113(2):115-21. PubMed ID: 15115666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.